Market Trends Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 (DYN:NASDAQ)By admin8996erT0allMarch 17, 2025 Dyne Therapeutics (NASDAQ:DYN) on Monday reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating…
